Pulmonary embolisms are dangerous, lung-clogging blot clots. In a pilot study, scientists at the Icahn School of Medicine at Mount Sinai showed for the first time that artificial intelligence (AI) algorithms can detect signs of these clots in electrocardiograms (EKGs), a finding which may one day help doctors with screening.
The results published in the European Heart Journal – Digital Health suggested that new machine learning algorithms, which are designed to exploit a combination of EKG and electronic health record (EHR) data, may be more effective than currently used screening tests at determining whether moderate- to high-risk patients actually have pulmonary embolisms.
The study was led by Sulaiman S. Somani, MD, a former medical student in the lab of Benjamin S. Glicksberg, PhD, Assistant Professor of Genetics and Genomic Sciences and a member of the Hasso Plattner Institute for Digital Health at Mount Sinai.
Pulmonary embolisms happen when deep vein blood clots, usually formed in the legs or arms, break away and clog lung arteries. These clots can be lethal or cause long-term lung damage. Although some patients may experience shortness of breath or chest pain, these symptoms may also signal other problems that have nothing to do with blood clots, making it difficult for doctors to properly diagnose and treat cases. Moreover, current official diagnoses rely on computed tomography pulmonary angiograms (CTPAs), which are time-consuming chest scans that can only be performed at select hospitals and require patients to be exposed to potentially dangerous levels of radiation.
To make diagnoses easier and more accessible, researchers have spent more than 20 years developing advanced computer programs, or algorithms, designed to help doctors determine whether at-risk patients are actually experiencing pulmonary embolisms. The results have been mixed. For example, algorithms that used EHRs have produced a wide range of success rates for accurately detecting clots and can be labor-intensive. Meanwhile, the more accurate ones depend heavily on data from the CTPAs.
In this study the researchers found that fusing algorithms that rely on EKG and EHR data may be an effective alternative, because EKGs are widely available and relatively easy to administer.
The researchers created and tested out various algorithms on data from 21,183 Mount Sinai Health System patients who showed moderate to highly suspicious signs of having pulmonary embolisms. While some algorithms were designed to use EKG data to screen for pulmonary embolisms, others were designed to use EHR data. In each situation, the algorithm learned to identify a pulmonary embolism case by comparing either EKG or EHR data with corresponding results from CTPAs. Finally, a third, fusion algorithm was created by combining the best-performing EKG algorithm with the best-performing EHR one.
The results showed that the fusion model not only outperformed its parent algorithms but was also better at identifying specific pulmonary embolism cases than the Wells' Criteria Revised Geneva Score and three other currently used screening tests. The researchers estimated that the fusion model was anywhere from 15 to 30 percent more effective at accurately screening acute embolism cases, and the model performed best at predicting the most severe cases. Furthermore, the fusion model's accuracy remained consistent regardless of whether race or sex was tested as a factor, suggesting it may be useful for screening a variety of patients.
According to the authors, these results support the theory that EKG data may be effectively incorporated into new pulmonary embolism screening algorithms. They plan to further develop and test these algorithms out for potential utility in the clinic.
Who: Benjamin S. Glicksberg, PhD, Assistant Professor of Genetics and Genomic Sciences and a member of the Hasso Plattner Institute for Digital Health at Mount Sinai.
This study was support by the National Institutes of Health (TR001433).
Article:
Somani, S.S. et al., Development of a machine learning model using electrocardiogram signals to improve acute pulmonary embolism screening. European Heart Journal, November 25, 2021, DOI: 10.1093/ehjdh/ztab101
About the Mount Sinai Health System
The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai advances medicine and health through unrivaled education and translational research and discovery to deliver care that is the safest, highest-quality, most accessible and equitable, and the best value of any health system in the nation. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture ambulatory surgery centers; more than 415 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. The Mount Sinai Hospital is ranked on U.S. News & World Report's "Honor Roll" of the top 20 U.S. hospitals and is top in the nation by specialty: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. Mount Sinai Kravis Children's Hospital is ranked in U.S. News & World Report's "Best Children's Hospitals" among the country's best in four out of 10 pediatric specialties. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report's "Best Medical Schools," aligned with a U.S. News & World Report "Honor Roll" Hospital, and No. 14 in the nation for National Institutes of Health funding. Newsweek's "The World's Best Smart Hospitals" ranks The Mount Sinai Hospital as No. 1 in New York and in the top five globally, and Mount Sinai Morningside in the top 20 globally.
